Consensus aTyr Pharma, Inc.

Equities

LIFE

US0021202025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
1.6 ^USD	-1.23%		-8.05%	+13.48%

Mar. 15	RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier	MT
Mar. 14	Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024

Evolution of the average Target Price on aTyr Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e815ad333.yMNwLTwblvjXP8hncK8hfN8mA_aODTOhvSt_5iopHfA.hqsvZWlP8oinEqw-Ieh3FrYSQZu9bELF7WQsqkxxSb6tkiMbbC7GtI5pvw~263a9c130bc335c29a6a6717e8ce1426

Analyst Recommendations on aTyr Pharma, Inc.

RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier	Mar. 15	MT
Piper Sandler Adjusts Price Target on aTyr Pharma to $20 From $13, Maintains Overweight Rating	23-07-21	MT
Oppenheimer Downgrades aTyr Pharma to Perform From Outperform, Removes $17 Price Target	23-07-05	MT
Piper Sandler Adjusts Price Target on aTyr Pharma to $13 From $9, Keeps Overweight Rating	23-04-11	MT
Roth MKM Reinstates aTyr Pharma at Buy With $9 Price Target	23-03-06	MT
RBC Cuts Price Target on aTyr Pharma to $19 From $20, Maintains Outperform, Speculative Risk	23-03-02	MT
Oppenheimer Adjusts aTyr Pharma Price Target to $25 From $21, Maintains Outperform Rating	22-08-16	MT
Piper Sandler Adjusts Price Target on aTyr Pharma to $14 From $11, Reiterates Overweight Rating	22-08-16	MT
HC Wainwright Adjusts Price Target on aTyr Pharma to $35 From $11, Reiterates Buy Rating	22-07-21	MT
Piper Sandler Adjusts ATyr Pharma's Price Target to $11 From $19, Reiterates Overweight Rating	22-05-18	MT
RBC Cuts Price Target on ATyr Pharma to $20 From $22, Maintains Outperform-Speculative Risk Rating	22-05-10	MT
HC Wainwright Adjusts aTyr Pharma's Price Target to $11 from $18, Keeps Buy Rating	21-11-11	MT
ATYR PHARMA : RBC Initiates aTyr Pharma at Outperform, Speculative Risk, Sets Price Target at $22, Says Lead Product is Underappreciated	21-10-12	MT
ATYR PHARMA : Piper Sandler Starts aTyr Pharma at Overweight With $19 Price Target	21-09-21	MT
ATYR PHARMA : Roth Capital Adjusts aTyr Pharma's Price Target to $21 from $20, Keeps Buy Rating	21-09-14	MT
ATYR PHARMA : Oppenheimer Adjusts aTyr Pharma PT to $20 From $14 as ATYR1923 Pulmonary Sarcoidosis Results Surpass Expectations, Maintains Outperform Rating	21-09-14	MT
ATYR PHARMA : Jones Trading Adjusts Price Target for aTyr Pharma to $20 From $15, Maintains Buy Rating	21-09-13	MT
ATYR PHARMA : HC Wainwright Adjusts aTyr Pharma PT to $18 From $13, Maintains Buy Rating	21-09-13	MT
ATYR PHARMA : JonesTrading Initiates Coverage on ATyr Pharma With Buy Rating, $15 Price Target	21-05-18	MT
ATYR PHARMA : Laidlaw Starts ATyr Pharma at Buy With $18 Price Target	21-05-10	MT
ATYR PHARMA : Oppenheimer Adjusts ATyr Pharma's Price Target to $14 From $12, Keeps Outperform Rating	21-03-24	MT
ATYR PHARMA : Roth Capital Adjusts aTyr Pharma PT to $20 From $15, Maintains Buy Rating	21-03-16	MT